The goal of this observational study is to determine whether metabolomic profiles combined with clinical data can predict high-flow nasal cannula (HFNC) failure and help optimize respiratory support in adult patients with acute hypoxemic respiratory failure (AHRF). The main questions it aims to answer are:
Can metabolomic biomarkers identify patients at higher risk of HFNC failure? Does combining metabolomic and clinical data improve the prediction of respiratory support escalation and clinical outcomes?
Participants will:
Receive standard HFNC treatment according to clinical practice. Undergo collection of clinical, physiological, and laboratory data. Provide blood samples for metabolomic analysis during respiratory support.
Adult patients (≥18 years old).
Admission to the intensive care unit (ICU) with acute hypoxemic respiratory failure (AHRF).
Treatment with high-flow nasal cannula (HFNC) as the initial respiratory support strategy.
Inclusion within the first 24 hours after HFNC initiation.
Age <18 years.
Active do-not-resuscitate (DNR) orders or limitation of therapeutic effort.
Refusal or inability to provide informed consent.
Previous invasive mechanical ventilation before study inclusion.
Hospital del Mar Research Institute (IMIM)
Lead sponsor
Instituto de Salud Carlos III
Collaborator
Fundació La Marató de TV3
Collaborator
Hospital Universitari de Bellvitge
Collaborator
Hospital Universitari Joan XXIII de Tarragona.
Collaborator
Parc Taulí Hospital Universitari
Collaborator
Institute for Bioengineering of Catalonia
Collaborator